blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3202909

EP3202909 - CANCER SPECIFIC-SPLICING RIBOZYME AND USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.07.2020
Database last updated on 10.08.2024
FormerThe patent has been granted
Status updated on  24.05.2019
FormerGrant of patent is intended
Status updated on  10.04.2019
FormerRequest for examination was made
Status updated on  07.07.2017
FormerThe international publication has been made
Status updated on  28.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
RZNOMICS INC.
Room 314, 152, Jukjeon-ro
Suji-gu
Yongin-si, Gyeonggi-do / KR
[2018/02]
Former [2017/32]For all designated states
Industry-Academic Cooperation Foundation Dankook University
Dankook Univ.
Jukjeon-dong
152 Jukjeon-ro
Suji-gu
Yongin-si, Gyeonggi-do 448-701 / KR
Inventor(s)01 / LEE, Seong Wook
121-602
16 Hwarang-ro 48-gil
Seongbuk-gu
Seoul 136-761 / KR
02 / KIM, Ju Hyun
2-701
1102 Gyeongsu-daero
Jangan-gu
Suwon-si Gyeonggi-do 440-851 / KR
03 / JEONG, Jin Sook
208-1904
113 Bunpo-ro
Nam-gu
Busan 608-784 / KR
04 / HAN, Sang Young
104-602
15 Daecheon-ro 67beon-gil
Haeundae-gu
Busan 612-791 / KR
 [2017/32]
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2017/32]
Application number, filing date15847264.723.07.2015
[2017/32]
WO2015KR07694
Priority number, dateKR2014013028629.09.2014         Original published format: KR 20140130286
KR2014018597622.12.2014         Original published format: KR 20140185976
[2017/32]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016052851
Date:07.04.2016
Language:KO
[2016/14]
Type: A1 Application with search report 
No.:EP3202909
Date:09.08.2017
Language:EN
[2017/32]
Type: B1 Patent specification 
No.:EP3202909
Date:26.06.2019
Language:EN
[2019/26]
Search report(s)International search report - published on:KR07.04.2016
(Supplementary) European search report - dispatched on:EP23.04.2018
ClassificationIPC:C12N15/85, C12N9/22, A61K31/713, A61K38/43, A61P35/00
[2017/32]
CPC:
A61K31/713 (EP,KR,US); C12N15/85 (EP,KR,US); C12N15/113 (KR,US);
A61K38/43 (EP,US); A61K48/0058 (US); A61K48/0066 (US);
A61P35/00 (EP); C07K14/4705 (US); C12N15/1135 (EP,US);
C12N15/63 (US); C12N15/79 (US); C12N15/86 (EP,US);
C12N9/22 (EP,US); A61K38/00 (EP,US); C07K2319/01 (US);
C07K2319/33 (US); C07K2319/61 (US); C12N2310/113 (EP,US);
C12N2310/12 (US); C12N2310/124 (EP,US); C12N2310/128 (US);
C12N2330/51 (EP,US); C12N2710/10343 (EP,US); C12N2830/008 (EP,US);
C12N2830/42 (EP,US); C12N2830/48 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/32]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:KREBSSPEZIFISCHES SPLICING-RIBOZYM UND VERWENDUNG DAVON[2017/32]
English:CANCER SPECIFIC-SPLICING RIBOZYME AND USE THEREOF[2017/32]
French:RIBOZYME À ÉPISSAGE SPÉCIFIQUE DU CANCER, ET SON UTILISATION[2017/32]
Entry into regional phase27.04.2017Translation filed 
27.04.2017National basic fee paid 
27.04.2017Search fee paid 
27.04.2017Designation fee(s) paid 
27.04.2017Examination fee paid 
Examination procedure27.04.2017Examination requested  [2017/32]
27.04.2017Date on which the examining division has become responsible
15.11.2018Amendment by applicant (claims and/or description)
11.04.2019Communication of intention to grant the patent
17.05.2019Fee for grant paid
17.05.2019Fee for publishing/printing paid
17.05.2019Receipt of the translation of the claim(s)
Opposition(s)03.06.2020No opposition filed within time limit [2020/32]
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
25.06.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.07.2015
AL26.06.2019
AT26.06.2019
CY26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MK26.06.2019
MT26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
IE23.07.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
[2022/32]
Former [2021/34]HU23.07.2015
AL26.06.2019
AT26.06.2019
CY26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MT26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
IE23.07.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2021/33]HU23.07.2015
AL26.06.2019
AT26.06.2019
CY26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
IE23.07.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2021/26]AL26.06.2019
AT26.06.2019
CY26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
IE23.07.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/37]AL26.06.2019
AT26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
IE23.07.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/36]AL26.06.2019
AT26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
IE23.07.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/25]AL26.06.2019
AT26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
LU23.07.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
PT28.10.2019
IS24.02.2020
Former [2020/24]AL26.06.2019
AT26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BE31.07.2019
CH31.07.2019
LI31.07.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
PT28.10.2019
IS24.02.2020
Former [2020/22]AL26.06.2019
AT26.06.2019
CZ26.06.2019
DK26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/17]AL26.06.2019
AT26.06.2019
CZ26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
NL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/13]AL26.06.2019
AT26.06.2019
CZ26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
NL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
SM26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/12]AL26.06.2019
AT26.06.2019
CZ26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
IT26.06.2019
LT26.06.2019
LV26.06.2019
NL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/11]AL26.06.2019
AT26.06.2019
CZ26.06.2019
EE26.06.2019
ES26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
NL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
SK26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
PT28.10.2019
Former [2020/10]AL26.06.2019
AT26.06.2019
CZ26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
NL26.06.2019
RO26.06.2019
RS26.06.2019
SE26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
PT28.10.2019
Former [2020/09]AL26.06.2019
CZ26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
NL26.06.2019
RS26.06.2019
SE26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
Former [2020/07]AL26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
NL26.06.2019
RS26.06.2019
SE26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
Former [2019/51]AL26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
SE26.06.2019
BG26.09.2019
NO26.09.2019
GR27.09.2019
Former [2019/50]AL26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
SE26.06.2019
NO26.09.2019
GR27.09.2019
Former [2019/49]AL26.06.2019
FI26.06.2019
HR26.06.2019
LT26.06.2019
SE26.06.2019
NO26.09.2019
Former [2019/48]FI26.06.2019
LT26.06.2019
SE26.06.2019
NO26.09.2019
Former [2019/47]FI26.06.2019
LT26.06.2019
NO26.09.2019
Documents cited:Search[Y]  - JEONG, JIN SOOK, ET AL., "Highly specific and effective HCC gene therapy based on cancer-specific RNA replacement via liver-specific microRNA regulation in mouse model.", HEPATHOLOGY, (20121001), vol. 56, no. Suppl.1, ISSN 0270-9139, page 793A, XP002779800 [Y] 1-15 * the whole document *
 [Y]  - KIM JU-HYUN ET AL, "ANTI- CANCER APPROACH THROUGH MICRORNA-REGULATED RNA REPLACEMENT", NUCLEIC ACID THERAPEU, MARY ANN LIEBERT, INC. PUBLISHERS, US, (20111001), vol. 21, no. 5, ISSN 2159-3337, page A17, XP009183471 [Y] 1-15 * the whole document *
 [Y]  - JEONG JIN SOOK ET AL, "In vivo HCC Gene therapy targeting by trans-splicing ribozyme and liver specific promoter with augumented safety", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, & 18TH WORLD CONGRESS ON ADVANCES IN ONCOLOGY / 16TH INTERNATIONAL SYMPOSIUM ON MOLECULAR MEDICINE; CRETE, GREECE; OCTOBER 10 -12, 2013, (2013), vol. 32, no. Suppl. 1, page S12, XP002779801 [Y] 1-15 * the whole document *
 [Y]  - XINPING FU ET AL, "Construction of an Oncolytic Herpes Simplex Virus That Precisely Targets Hepatocellular Carcinoma Cells", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20120201), vol. 20, no. 2, doi:10.1038/mt.2011.265, ISSN 1525-0016, pages 339 - 346, XP055465038 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/mt.2011.265
 [A]  - WON ET AL, "Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, (20070419), vol. 129, no. 4, doi:10.1016/J.JBIOTEC.2007.02.004, ISSN 0168-1656, pages 614 - 619, XP022034272 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jbiotec.2007.02.004
 [XP]  - JUHYUN KIM ET AL, "Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA Regulation", SCIENTIFIC REPORTS, (20150720), vol. 5, doi:10.1038/srep12315, page 12315, XP055275537 [XP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/srep12315
 [XP]  - JEONG JIN-SOOK ET AL, "Efficient and Safe HCC-specific Gene Therapy and Its Possible Role of Immunogenic Cell Death via Adenovirus Harboring mTERT-targeting Trans-splicing Ribozyme, Liver-specific Promoter and MicroRNA Regulation in Immunocompetent Mouse", HEPATOLOGY, & 65TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES; BOSTON, MA, USA; NOVEMBER 07 -11, 2014, (2014), vol. 60, no. Suppl. 1, Sp. Iss. SI, page 827A, XP002779802 [XP] 1-15 * the whole document *
 [XP]  - KIM JU-HYUN ET AL, "Development of cancer gene therapy based on cancer-specific RNA replacement through microRNA regulation", HUMAN GENE THERAPY, & ESGCT AND NVGCT COLLABORATIVE CONGRESS; THE HAGUE, NETHERLANDS; OCTOBER 23 -26, 2014, (201411), vol. 25, no. 11, pages A80 - A81, XP002779803 [XP] 1-15 * the whole document *
International search[A]KR20100024055  (IND ACADEMIC COOP [KR]) [A] 1-14* See abstract *;
 [Y]KR20120132594  (INDUSTRY-ACADEMIC COOPERATION FOUNDATION, DANKOOK UNIVERSITY) [Y] 1-14 * See the entire document, especially abstract; the claims; paragraph [0018] etc. *;
 [Y]  - LIM, JI YEONG, "Studies on the Improvement of Efficacy of Trans-Splicing Ribozyme for Cancer Therapy based on Group I Intron of Tetrahymena Thermophila", Master's Thesis of Graduate School of Dankook University, (20120000) [Y] 1-14 * See the entire document *
 [YA]  - KWON, B-S. et al., "Specific Regression of Human Cancer Cells by Ribozyme-Mediated Targeted Replacement of Tumor-Specific Transcript", Molecular Therapy, (20051100), vol. 12, no. 5, doi:doi:10.1016/j.ymthe.2005.06.096, pages 824 - 834, XP005126644 [Y] 2, 12-14 * See the entire document * [A] 1, 3-11

DOI:   http://dx.doi.org/10.1016/j.ymthe.2005.06.096
 [YA]  - "Herpes simplex virus type 1 thymidine kinase and 3KBL genes", GenBan k, (19930802), Database accession no. J02224.1 [Y] 9, 12-14 * See the entire document * [A] 1-8, 10, 11
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.